TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28408067

Group type: EXPERIMENTAL
Intervention: Polyphenol supplementation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 28
Study: 26819200

Group type: COMPARATOR
Intervention: Total 100 % energy restriction (ER)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Partial 75 % energy restriction (ER)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Isoenergetic intake
Number of subjects: 10
Study: 23937144

Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise (80% of 1RM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Moderate-intensity resistance exercise (50% of 1RM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control session (rest)
Number of subjects: 10
Study: 22788842

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (N = 36)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Tacrolimus (N = 34)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Both Cyclosporine A and Tacrolimus
Number of subjects: 70
Study: 20427683

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Hyperbaric air (placebo)
Number of subjects: 94
Study: 18176223

Group type: EXPERIMENTAL
Intervention: Bone morphogenetic protein-2 (BMP-2)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Traditional iliac crest bone graft
Number of subjects: 21
Study: 15923414

Group type: EXPERIMENTAL
Intervention: Home Treatment (HT) with low molecular weight heparin (LMWH) followed by warfarin
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Home Treatment (HT) with low molecular weight heparin (LMWH) alone
Number of subjects: 207

Group type: COMPARATOR
Intervention: Hospitalized treatment with LMWH and warfarin
Number of subjects: 207

Group type: COMPARATOR
Intervention: Hospitalized treatment with LMWH alone
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Home Treatment (HT)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Hospitalized treatment
Number of subjects: 207
Study: 12607659

Group type: EXPERIMENTAL
Intervention: etodolac
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: diclofenac
Number of subjects: 60

Group type: COMPARATOR
Intervention: tramadol
Number of subjects: 60
Study: 10232435

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 23
Study: 8909629

Group type: EXPERIMENTAL
Intervention: PeaceBuilders intervention implemented in four schools starting in Year 1
Number of subjects: 2736

Group type: COMPARATOR
Intervention: Control group (four schools starting PeaceBuilders in Year 2)
Number of subjects: 2736
Study: 1882906

Group type: EXPERIMENTAL
Intervention: sucralfate, 1 g q.i.d., 0.5 hour before meals on an empty stomach or at bedtime
Number of subjects: 90

Group type: COMPARATOR
Intervention: ranitidine, 150 mg b.i.d.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: sucralfate, 1 g b.i.d. (before breakfast and at bedtime)
Number of subjects: 90

Group type: COMPARATOR
Intervention: ranitidine, 150 mg at bedtime
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: sucralfate
Number of subjects: 90

Group type: COMPARATOR
Intervention: ranitidine
Number of subjects: 90
Study: 7057465

Group type: EXPERIMENTAL
Intervention: Supplemental albumin therapy
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Supplemental steroid therapy
Number of subjects: 184
Study: 31085528

Group type: EXPERIMENTAL
Intervention: Parent-targeted online intervention combining microbiological local syndromic surveillance data, symptom information, and home-care advice
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Parent-targeted online intervention
Number of subjects: 806

Group type: COMPARATOR
Intervention: Control group (received material after answering questions)
Number of subjects: 806
Study: 28674829

Group type: EXPERIMENTAL
Intervention: 4 Hz-matrix stimulation (EC2) with 5 min duration and 1200 stimuli
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 4 Hz-matrix stimulation (EC1) with 2.5 min duration and 600 stimuli
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no stimulation)
Number of subjects: 30
Study: 26369473

Group type: EXPERIMENTAL
Intervention: Surgery (gastric bypass)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Surgery (biliopancreatic diversion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 60
Study: 24388622

Group type: EXPERIMENTAL
Intervention: ezetimibe + fluvastatin (10 mg/day + 30 mg/day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: fluvastatin alone (30 mg/day)
Number of subjects: 63
Study: 22107110

Group type: EXPERIMENTAL
Intervention: Text message programme targeted at changing illness and medication beliefs over 18 weeks
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Text message programme
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group (no text messages)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Intervention group (text message programme)
Number of subjects: 216
Study: 19243710

Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride nasal spray 0.6% (OLO)
Number of subjects: 544

Group type: COMPARATOR
Intervention: Azelastine hydrochloride nasal spray 0.1% (AZE)
Number of subjects: 544

Group type: COMPARATOR
Intervention: Inactive vehicle (placebo control)
Number of subjects: 544
Study: 18163018

Group type: EXPERIMENTAL
Intervention: Colchicine (1.0 mg twice daily for the first day followed by 0.5 mg twice daily for 1 month for patients ≥70 kg; halved doses for patients <70 kg or intolerant)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 360
Study: 15195238

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza virus vaccine (TVV) + Trivalent live cold‐adapted influenza virus vaccine (CAIV-T)
Number of subjects: 2215

Group type: COMPARATOR
Intervention: Trivalent inactivated influenza virus vaccine (TVV) + Placebo (P)
Number of subjects: 2215
Study: 11375845

Group type: EXPERIMENTAL
Intervention: Continuous thoracic epidural anesthesia (TEA) with 0.2% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 60
Study: 9790376

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 2503

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2503
Study: 7659479

Group type: EXPERIMENTAL
Intervention: HbOC (Haemophilus b oligosaccharide conjugate vaccine) administered simultaneously with DTaP or DTP
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTaP vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTP vaccines
Number of subjects: 0
Study: 2697585

Group type: EXPERIMENTAL
Intervention: MP/IFN
Number of subjects: 158

Group type: COMPARATOR
Intervention: MP
Number of subjects: 158
Study: 1094544

Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 40
Study: 30092827

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) + Methotrexate (MTX)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 90
Study: 27804264

Group type: EXPERIMENTAL
Intervention: Weight Watchers program (WW) with telephone and email consultations from a certified diabetes educator
Number of subjects: 563

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 563
Study: 23992556

Group type: EXPERIMENTAL
Intervention: Broccoli consumption (250 g/day for 10 days)
Number of subjects: 100
Study: 23457987

Group type: EXPERIMENTAL
Intervention: Extended program of social and hygienic monitoring including risk factors for diseases based on lifestyle and periodic health examination groups.
Number of subjects: 0
Study: 20230136

Group type: EXPERIMENTAL
Intervention: Group Reminiscence (GR)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Individual Reminiscence (IR)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Group Control Activity (C)
Number of subjects: 73
Study: 18372433

Group type: EXPERIMENTAL
Intervention: Iloprost 50 microg twice daily
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Iloprost 100 microg twice daily
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Iloprost 150 microg twice daily
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 430

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study: 15720350

Group type: EXPERIMENTAL
Intervention: Cold biopsy followed by bipolar electrocoagulation (Group A) using a 10 Fr catheter with setting 8 (40 W) for 1 second.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional monopolar hot biopsy forceps (Group B).
Number of subjects: 50
Study: 11333166

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 199
Study: 9443519

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (1.5 mg/kg caffeine/body weight)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 46

Group type: COMPARATOR
Intervention: Fruit juice
Number of subjects: 46
Study: 8197032

Group type: EXPERIMENTAL
Intervention: Ticarcillin-clavulanic acid (T-C) 3.1 g
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ampicillin-sulbactam (A-S) 3 g
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ticarcillin-clavulanic acid (T-C)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ampicillin-sulbactam (A-S)
Number of subjects: 9
Study: 3295035

Group type: EXPERIMENTAL
Intervention: Captopril (25 or 50 mg given thrice daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg given thrice daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Captopril plus Indomethacin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Captopril alone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2676528

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67

Group type: COMPARATOR
Intervention: Balanced anaesthesia
Number of subjects: 67
Study: 31759036

Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (LBC)
Number of subjects: 170
Study: 31119481

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 43
Study: 28011207

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study: 25133822

Group type: COMPARATOR
Intervention: Standard invitation letter
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Invitation letter with vouchers worth 45 for undergoing 3 vaccinations
Number of subjects: 1000
Study: 23240706

Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 29
Study: 22118479

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Epidermal growth factor (EGF) via Gelfoam patching
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Edge-approximation plus Gelfoam patching
Number of subjects: 291
Study: 19731125

Group type: EXPERIMENTAL
Intervention: Tailored message
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Generic message
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Targeted message
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control message
Number of subjects: 217
Study: 17383080

Group type: COMPARATOR
Intervention: BCG RIVM 2 x 10(8) CFU weekly for 6 wk
Number of subjects: 495

Group type: COMPARATOR
Intervention: MMC 20 mg weekly for 6 wk
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: MMC 20 mg weekly for 6 wk followed by monthly instillations for 3 yr
Number of subjects: 495
Study: 15109047

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 0
Study: 11207651

Group type: EXPERIMENTAL
Intervention: Albendazole treatment group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCG vaccination in treated group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study: 9669255

Group type: EXPERIMENTAL
Intervention: Immediate angioplasty (2 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Delayed angioplasty (3 months)
Number of subjects: 16
Study: 7596767

Group type: EXPERIMENTAL
Intervention: 30 Gy/10 fractions/2 weeks (group A)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 50 Gy/20 fractions/4 weeks (group B)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 30 Gy/10 fractions/2 weeks (group C)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 20 Gy/5 fractions/1 week (group D)
Number of subjects: 162
Study: 3042835

Group type: EXPERIMENTAL
Intervention: rt-PA (70 mg with an initial bolus of 10 mg)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Urokinase (3 million units with an initial bolus of 1.5 million units)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 246

Group type: COMPARATOR
Intervention: Urokinase
Number of subjects: 246
Study: 30866910

Group type: EXPERIMENTAL
Intervention: Digital impressions (3M, St. Paul, NM)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional impressions (alginate)
Number of subjects: 31
Study: 29362596

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (30 ml/day for 10 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 26004611

Group type: EXPERIMENTAL
Intervention: EMG biofeedback treatment after BTX-A injection
Number of subjects: 36

Group type: COMPARATOR
Intervention: Botulinum toxin-A (BTX-A) injection
Number of subjects: 36
Study: 23911217

Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate (LC) diet
Number of subjects: 47

Group type: COMPARATOR
Intervention: High-carbohydrate (HC) diet
Number of subjects: 47
Study: 22094835

Group type: EXPERIMENTAL
Intervention: 60 mg iron as ferrous sulfate
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 60 mg iron as NaFeEDTA
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 153
Study: 19362994

Group type: EXPERIMENTAL
Intervention: Benfluorex (BFL) 3 tablets/day for 24 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 22
Study: 16314385

Group type: EXPERIMENTAL
Intervention: Pro-active call centre-based stepped treatment support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tele-care intervention
Number of subjects: 0
Study: 16281462

Group type: EXPERIMENTAL
Intervention: Use of Data Monitoring Committees (DMCs)
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Planned interim analyses
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: At least one of DMC use or interim analyses
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Comparison of DMC use between 2000 and 1990
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Factors associated with increased DMC use
Number of subjects: 662
Study: 11401971

Group type: EXPERIMENTAL
Intervention: MACconj (meningococcal group A+C conjugate vaccine)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: MACPS (meningococcal group A+C polysaccharide vaccine)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: MACconj booster after MACconj priming
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: MACPS booster after MACPS priming
Number of subjects: 195
Study: 8988699

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 10 mg
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 20 mg
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 8215864

Group type: EXPERIMENTAL
Intervention: Ankle joint angle feedback and EMG biofeedback from the soleus muscle
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional physical therapy (PT)
Number of subjects: 8
Study: 3307567

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate (CM) 4.0 mg orally, 4 times daily for 4 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride (DH) 2 mg intranasally, 4 times daily for 5 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 29740097

Group type: EXPERIMENTAL
Intervention: 18F-FET PET
Number of subjects: 26

Group type: COMPARATOR
Intervention: MRI-derived gross tumor volumes (GTV)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: FLAIR hyperintense area
Number of subjects: 26
Study: 26931331

Group type: EXPERIMENTAL
Intervention: Anterior transpedicular screw fixation (ATPS)
Number of subjects: 50
Study: 24898640

Group type: EXPERIMENTAL
Intervention: Screened positive for dementia (DemTect < 9)
Number of subjects: 243
Study: 23649080

Group type: EXPERIMENTAL
Intervention: 40 mg sublingual piroxicam (two 20‐mg tablets once daily on the first and second postoperative days, followed by one 20‐mg tablet on the third postoperative day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 150 mg oral diclofenac (50 mg thrice a day on the first, second, and third postoperative days)
Number of subjects: 100
Study: 20199243

Group type: EXPERIMENTAL
Intervention: Local hyperthermia at 44 degrees C for 30 min a day for 3 consecutive days plus 2 additional days 2 weeks later
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 54
Study: 18814452

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 403

Group type: COMPARATOR
Intervention: Montelukast 10 mg
Number of subjects: 403

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study: 16197669

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 60 mg twice daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg once daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12114372

Group type: EXPERIMENTAL
Intervention: BAYx1005 (500 mg bid)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 10206217

Group type: EXPERIMENTAL
Intervention: Intravenously administered procainamide hydrochloride
Number of subjects: 70

Group type: COMPARATOR
Intervention: Direct current shock
Number of subjects: 70
Study: 7781621

Group type: EXPERIMENTAL
Intervention: Stricter guidelines for diagnosis and treatment of gestational diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term follow-up evaluation for women with gestational diabetes and their children
Number of subjects: 0
Study: 2193275

Group type: EXPERIMENTAL
Intervention: Home uterine activity monitoring and perinatal nursing support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education regarding the detection and reporting of preterm labor symptomatology
Number of subjects: 0
Study: 698029

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control/Placebo
Number of subjects: 78
Study: 31633254

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ketamine and Midazolam (comparison)
Number of subjects: 30
Study: 31212248

Group type: EXPERIMENTAL
Intervention: Sertraline (∼1 μg L‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methamphetamine (∼1 μg L‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (unexposed)
Number of subjects: 0
Study: 29492054

Group type: EXPERIMENTAL
Intervention: Intermittent cervical traction in sitting position along with TENS and hot pack (Group-A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intermittent cervical traction in supine position along with TENS and hot pack (Group-B)
Number of subjects: 40
Study: 27506203

Group type: EXPERIMENTAL
Intervention: Reinforcement-Induced Movement Therapy (RIMT) with goal-oriented movement amplification in VR
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group with the same training protocol but without movement amplification
Number of subjects: 18
Study: 24824360

Group type: EXPERIMENTAL
Intervention: Tryptophan intake of 15 mg·kg·day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Elemental formula
Number of subjects: 30

Group type: COMPARATOR
Intervention: Recommended intake of 29 mg·kg·day
Number of subjects: 30
Study: 23227501

Group type: EXPERIMENTAL
Intervention: Remaxol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 20089937

Group type: EXPERIMENTAL
Intervention: Topiramate 25 mg/kg/d
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Topiramate 15 mg/kg/d
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Topiramate 5 mg/kg/d
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 18975532

Group type: EXPERIMENTAL
Intervention: Sevoflurane with nitrous oxide (Group G)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sevoflurane with air (Group A)
Number of subjects: 20
Study: 15983916

Group type: COMPARATOR
Intervention: Therapeutic interleukin-2
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose prednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etanercept (a soluble TNF receptor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-TNF antibody infliximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiretroviral therapy
Number of subjects: 0
Study: 11915001

Group type: EXPERIMENTAL
Intervention: 100% adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 80%-99% adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0%-79% adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100% adherence at 3 follow-up visits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100% adherence at 2 follow-up visits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100% adherence at 1 follow-up visit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100% adherence at 0 follow-up visits
Number of subjects: 0
Study: 10037565

Group type: EXPERIMENTAL
Intervention: Entoptic perimetry
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fundus photography
Number of subjects: 32
Study: 7744158

Group type: EXPERIMENTAL
Intervention: Sedation only
Number of subjects: 46

Group type: COMPARATOR
Intervention: Operating room setting
Number of subjects: 46
Study: 1481832

Group type: EXPERIMENTAL
Intervention: Folinic acid (dl-Leucovorin, 15 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21